Search results for "TC"

showing 10 items of 9993 documents

Polymorphisms of the angiotensinogen gene and the outcome of microalbuminuria in essential hypertension: a 3-year follow-up study.

2003

Background: The objective of this study was to analyse the relationship of polymorphisms of the angiotensinogen (AGT) gene with the changes in microalbuminuria during 3 years of antihypertensive treatment in a group of young adults with essential hypertension. Methods: Essential hypertensives, less than 50 years old, never previously treated with antihypertensive drugs and in the absence of diabetes mellitus were included. After the initial evaluation, patients were treated using only nonpharmacological measures (n=23), only β-blockers (n=26), only angiotensin-converting enzyme inhibitors (ACEi) (n=57) or a combination of treatments (n=25). The office blood pressure, biochemical profile and…

AdultBlood GlucoseMalemedicine.medical_specialtyTime FactorsGenotypeAdrenergic beta-AntagonistsAngiotensinogenAngiotensin-Converting Enzyme InhibitorsBlood PressureEssential hypertensionExcretionDiabetes mellitusInternal medicineInternal MedicinemedicineAlbuminuriaHumansAntihypertensive AgentsProteinuriaPolymorphism Geneticbusiness.industrymedicine.diseaseEndocrinologyBlood pressureTreatment OutcomeACE inhibitorHypertensionMicroalbuminuriaFemaleGene polymorphismmedicine.symptombusinessmedicine.drugFollow-Up StudiesJournal of human hypertension
researchProduct

The effect of growth hormone ( GH ) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real‐life data from th…

2015

SummaryObjective To assess the effect of 4 years’ growth hormone (GH) replacement on glucose homeostasis and evaluate factors affecting glycosylated haemoglobin (HbA1c) in adults with growth hormone deficiency (GHD). Design NordiNet® International Outcome Study, a noninterventional study, monitors long-term effectiveness and safety of GH replacement [Norditropin® (somatropin), Novo Nordisk A/S] in real-life clinical practice. Patients Nondiabetic patients (n = 245) with adult-onset GHD (age ≥20 years at GH start), ≥4 years’ GH replacement and HbA1c values at baseline and 4 years were included in the analysis. Measurements Changes from baseline (∆) to 4 years in HbA1c, fasting plasma glucose…

AdultBlood GlucoseMalemedicine.medical_specialtyWaistendocrine system diseasesHormone Replacement TherapyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematologyGrowth hormone deficiencyImpaired glucose toleranceYoung Adult03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusDiabetes MellitusmedicineHomeostasisHumansGlucose homeostasisYoung adultAgedAged 80 and overGlycated Hemoglobinbusiness.industrynutritional and metabolic diseasesMiddle Agedmedicine.diseaseSomatropinTreatment OutcomeEndocrinologyGrowth HormoneFemalebusinessBody mass indexClinical Endocrinology
researchProduct

Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.

2008

BACKGROUND: Insulin glargine is a once-daily basal insulin analog with prolonged duration of action and absence of an evident peak. Glargine is associated with reduced frequency of hypoglycemic episodes (mostly nocturnal) as well as effective glycemic control. Maintenance of good metabolic control before conception and throughout pregnancy is essential to lower the risk of fetal malformations. Glargine might be a valuable alternative in the management of pregnancies complicated by diabetes mellitus. However, because its clinical utility has not been established, the use of glargine is not currently recommended during pregnancy. OBJECTIVE: The aim of this study was to retrospectively evaluat…

AdultBlood Glucosemedicine.medical_specialtyInsulin IsophanePregnancy in DiabeticsInsulin GlargineSettore MED/13 - EndocrinologiaInsulin aspartPregnancyDiabetes mellitusInternal medicinemedicineOutpatient clinicInsulin lisproHumansHypoglycemic AgentsInsulinPharmacology (medical)Body Weights and MeasuresFemurInsulin AspartGlycemicRetrospective StudiesPharmacologyGlycated HemoglobinType 1 diabetesPregnancyInsulin LisproInsulin glarginebusiness.industryglargine type 1 diabetesPregnancy Outcomemedicine.diseaseInsulin Long-ActingEndocrinologyDiabetes Mellitus Type 1Case-Control StudiesFemalebusinessmedicine.drugClinical therapeutics
researchProduct

Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?

2018

Randomized trials have not focused on neonatal complications of glyburide for women with gestational diabetes.To compare oral glyburide vs subcutaneous insulin in prevention of perinatal complications in newborns of women with gestational diabetes.The Insulin Daonil trial (INDAO), a multicenter noninferiority randomized trial conducted between May 2012 and November 2016 (end of participant follow-up) in 13 tertiary care university hospitals in France including 914 women with singleton pregnancies and gestational diabetes diagnosed between 24 and 34 weeks of gestation.Women who required pharmacologic treatment after 10 days of dietary intervention were randomly assigned to receive glyburide …

AdultBlood Glucosemedicine.medical_specialtyendocrine system diseasesInjections Subcutaneousmedicine.medical_treatmentAdministration Oral030209 endocrinology & metabolism.OverweightInfant Newborn DiseasesFetal Macrosomia03 medical and health sciences0302 clinical medicinePharmacotherapyInsulin resistancePregnancyInternal medicineGlyburidemedicineHumansHypoglycemic AgentsInsulin030212 general & internal medicineFamily historyHyperbilirubinemiabusiness.industryInsulinInfant NewbornPregnancy Outcomenutritional and metabolic diseasesType 2 Diabetes MellitusGeneral Medicinemedicine.diseaseHypoglycemiafemale genital diseases and pregnancy complicationsGestational diabetesDiabetes GestationalEditorialEndocrinologyFemalemedicine.symptomMetabolic syndromebusinessAnnals of Translational Medicine
researchProduct

Curasan PRP kit vs. PCCS PRP system

2002

An important reason to improve methods of isolating platelet-rich plasma (PRP) is the potential use of autologous thrombocyte growth factors. In addition to discontinuous cell separation, two methods for extracting PRP that can be performed directly by the surgeon are now available. This study compared the suitability of these two methods for the preparation of PRP. Whole blood was drawn from 47 healthy donors (18 men, 29 women) aged 20-59 years (mean 29.9, SD 7.7). For each donor, PRP was separated by the PCCS method (PCCS Kit, 3i Implant Innovations, Palm Beach Gardens, FL, USA) and by the Curasan method (analogous to the PRP kit, Curasan, Kleinostheim, Germany). Thrombocyte counts differ…

AdultBlood PlateletsMaleMatched Pair AnalysisMatched-Pair AnalysisStatistics as TopicEfficiencyBuffy coatBiologyStatistics NonparametricInjectionsAndrologySex FactorsSex factorsThrombocyte countCatheterization PeripheralCell separationHumansPlateletGrowth SubstancesWhole bloodPlatelet CountSyringesPlateletpheresisAge FactorsAnticoagulantsEquipment DesignMiddle AgedNeedlesPlatelet-rich plasmaImmunologyFemaleOral SurgeryClinical Oral Implants Research
researchProduct

Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients

2006

A significant percentage of stage II melanoma patients (tumor thickness >1 mm) remain at risk of tumor recurrence after primary tumor excision. In this study, we used tumor antigen-pulsed dendritic cells as an adjuvant for immunization of these “high-risk” melanoma patients after resection of the primary tumor. A total of 13 patients were included and vaccinated 6 times every 14 days with autologous dendritic cells pulsed with a MelanA/MART-1 peptide in combination with a recall antigen. Antigen-specific immune responses were monitored before, during and up to 1 year after the last vaccination. The majority of patients exhibited increased recall antigen-specific CD4+ T cell responses upon v…

AdultCD4-Positive T-LymphocytesCancer ResearchSkin NeoplasmsT cellCD8-Positive T-LymphocytesCancer VaccinesMART-1 AntigenImmune systemAdjuvants ImmunologicAntigens NeoplasmHumansMedicineMelanomaCell Proliferationbusiness.industryMelanomaVaccinationDendritic CellsDendritic cellmedicine.diseasePrimary tumorTumor antigenNeoplasm ProteinsTreatment Outcomemedicine.anatomical_structureddc: 610OncologyImmunizationImmunologybusinessCD8International Journal of Cancer
researchProduct

Volume stability of hydroxyapatite and β-tricalcium phosphate biphasic bone graft material in maxillary sinus floor elevation: a radiographic study u…

2015

Objectives The purpose of this study was to confirm volume stability of biphasic calcium phosphate (BCP) through the changes of grafted volume over the time by 3D CT analyzing software program. Patients and Methods Fifteen patients, 16 sinuses who were scheduled a staged implantation through sinus floor elevation (SFE)–lateral window technique from 2009 to 2011 were included in the study. Of the 15 patients, eight were male and seven were female (mean age 50.1). For sinus floor augmentation, BCP with local blood was packed loosely into the maxillary sinus and the grafted site was covered with a collagen membrane. For the evaluation of volume change, 3D CBCT scans were taken five times at pr…

AdultCalcium PhosphatesMaleCone beam computed tomographySinus Floor Augmentationmedicine.medical_specialtyMaterials scienceMaxillary sinusRadiographySinus Floor AugmentationSinus floor elevation03 medical and health sciencesImaging Three-Dimensional0302 clinical medicinemedicineHumansProspective Studies030212 general & internal medicineAgedβ tricalcium phosphatebusiness.industry3d image processingMembranes Artificial030206 dentistryCone-Beam Computed TomographyMiddle AgedSurgeryDurapatiteTreatment Outcomemedicine.anatomical_structureVolume (thermodynamics)Bone SubstitutesRadiographic Image Interpretation Computer-AssistedFemaleCollagenOral SurgerybusinessBiomedical engineeringClinical Oral Implants Research
researchProduct

Retinoblastoma epidemiology: Does the evidence matter?

2007

It has been proposed that retinoblastoma is 'caused' by two sequential mutations affecting the RB1 gene, but this is a rather outdated view of cancer aetiology that does not take into account a large amount of new acquisitions such as chromosomal and epigenetic alterations. Retinoblastoma remains probably the only cancer in which the rather simplistic 'two hit' mutational model is still considered of value, although cancer is known to be associated with genomic and microsatellite instability, defects of the DNA mismatch repair system, alterations of DNA methylation and hystone acethylation/deacethylation, and aneuploidy. Moreover, as it is shown herein, the predictions made by the 'two hit'…

AdultCancer ResearchAdolescentRetinal NeoplasmsRetinoblastoma Aneuploidy Two hit theoryDiseaseBiologyAge DistributionChromosome instabilitymedicineHumansEpigeneticsAge of OnsetChildGerm-Line MutationGeneticsRetinoblastomaRetinoblastomaMicrosatellite instabilityCancerInfantMiddle Agedmedicine.diseasePedigreeSettore BIO/18 - GeneticaOncologyChild PreschoolDNA methylationDNA mismatch repair
researchProduct

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematolog…

2006

Abstract Purpose: LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle. Experimental Design: Fifteen patients (median age, 63 years; range, 42-87 years) with acute myeloid leukemia (13 patients), acute lymphocytic leukemia (1 patient), or myelodysplastic syndrome (1 patient) were treated with LBH589 at the following dose levels (mg/m2): 4.8 (3 patients), 7.2 (3 patients), 9.0 (1 patient), 11.5 (3 patient), and 14.0 (5 patients). The levels of histone acetylation were measured using quantitative flow cytometry and plasm…

AdultCancer ResearchIndolesMaximum Tolerated Dosemedicine.drug_classApoptosisPharmacologyHydroxamic AcidsDrug Administration ScheduleHistonesStructure-Activity Relationshipchemistry.chemical_compoundPredictive Value of TestsPanobinostatAcute lymphocytic leukemiaPanobinostatBiomarkers TumormedicineHumansEnzyme InhibitorsAgedCell ProliferationAged 80 and overDose-Response Relationship Drugbusiness.industryHistone deacetylase inhibitorArea under the curveQTcF ProlongationMyeloid leukemiaMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseHypokalemiaHistone Deacetylase InhibitorsLeukemiaTreatment OutcomeOncologychemistryCinnamatesLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseInjections IntravenousImmunologymedicine.symptombusinessFollow-Up StudiesClinical Cancer Research
researchProduct

EGFR and PCNA experession in oral squamous cell carcinomas—a valuable tool in estimating the patient's prognosis

1993

We investigated 100 cases of oral squamous cell carcinomas immunohistologically with respect to the expression of the epidermal growth factor receptor (EGFR) and the proliferating cell nuclear antigen (PCNA). The results were correlated with a new malignancy grading of the invasive tumour areas and the clinical outcome of the patients to estimate the individual prognosis. In conclusion, the amount of antigen expression of both antigens increases with the increasing grade of malignancy of the oral squamous cell carcinoma. Furthermore, there is a statistically significant correlation between the amount of antigen expression and the patient's prognosis. An overexpression of EGFR and PCNA is as…

AdultCancer ResearchPathologymedicine.medical_specialtyMalignancyAntigenPredictive Value of TestsEpidermal growth factorProliferating Cell Nuclear AntigenBiomarkers TumormedicineHumansNeoplasm InvasivenessProspective StudiesEpidermal growth factor receptorSurvival analysisNeoplasm StagingMouth neoplasmbiologyPrognosismedicine.diseaseImmunohistochemistrySurvival AnalysisProliferating cell nuclear antigenErbB ReceptorsGene Expression Regulation Neoplasticstomatognathic diseasesTreatment OutcomeOncologyCarcinoma Squamous CellCancer researchbiology.proteinImmunohistochemistryMouth NeoplasmsEuropean Journal of Cancer Part B: Oral Oncology
researchProduct